Surrozen (SRZN) Enterprise Value (2020 - 2026)
Surrozen (SRZN) posted quarterly Enterprise Value of -$106.9 million for Q1 2026, down 5.18% year-over-year from -$112.8 million in Q1 2025, and down 19.79% quarter-over-quarter from -$89.2 million in Q4 2025.
Surrozen (SRZN) Enterprise Value (2020 - 2026) Analysis & Trends
Surrozen's Enterprise Value history runs 7 years deep, the most recent figure standing at -$106.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 5.18% year-over-year to -$106.9 million; the TTM figure through Mar 2026 stood at -$106.9 million (down 5.18% YoY), while the FY2025 annual figure was -$89.2 million, down 158.19% from the prior year.
- Enterprise Value for Q1 2026 stood at -$106.9 million, down from -$89.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$27.3 million in Q1 2024, with the low at -$106.9 million in Q1 2026.
- The 5-year median for Enterprise Value is -$75.8 million (2022), against an average of -$66.7 million.
- The sharpest annual moves came in 2022 and 2024: Enterprise Value tumbled 391.72% in 2022, then jumped 55.8% in 2024.
- Surrozen's Enterprise Value stood at -$75.8 million in 2022, then surged by 52.47% to -$36.0 million in 2023, then grew by 4.1% to -$34.6 million in 2024, then slumped by 158.19% to -$89.2 million in 2025, then decreased by 19.79% to -$106.9 million in 2026.
- Business Quant data shows SRZN's Enterprise Value at -$106.9 million in Q1 2026, -$89.2 million in Q4 2025, and -$81.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -102.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.04 Mn |
| Mar 31, 2026 | -106.91 Mn |
| Dec 31, 2025 | -89.25 Mn |
| Sep 30, 2025 | -81.34 Mn |
| Jun 30, 2025 | -90.40 Mn |
| Mar 31, 2025 | -101.65 Mn |
| Dec 31, 2024 | -34.57 Mn |
| Sep 30, 2024 | -31.01 Mn |
| Jun 30, 2024 | -37.77 Mn |
| Mar 31, 2024 | -27.29 Mn |
| Dec 31, 2023 | -36.04 Mn |
| Sep 30, 2023 | -43.43 Mn |
| Jun 30, 2023 | -53.40 Mn |
| Mar 31, 2023 | -61.75 Mn |
| Dec 31, 2022 | -75.84 Mn |
| Sep 30, 2022 | -78.40 Mn |
| Jun 30, 2022 | -92.69 Mn |
| Mar 31, 2022 | -92.51 Mn |
| Dec 31, 2021 | -101.85 Mn |
| Sep 30, 2021 | -110.17 Mn |